CymaBay Therapeutics Inc. (CBAY) financial statements (2021 and earlier)

Company profile

Business Address 7575 GATEWAY BOULEVARD
NEWARK, CA 94560
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:146 179971742
Cash and cash equivalents28 4923108
Short-term investments118 13074934
Other undisclosed cash, cash equivalents, and short-term investments(0) 0(0)(3)0
Receivables   5 0
Prepaid expense3 3111
Other current assets  000 
Other undisclosed current assets3 (0)0(0)(0)
Total current assets:152 1821041943
Noncurrent Assets
Operating lease, right-of-use asset0 
Property, plant and equipment2 3000
Other noncurrent assets0 2110
Total noncurrent assets:2 5110
TOTAL ASSETS:154 1871041943
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9 6754
Accounts payable0 2111
Accrued liabilities5 4653
Employee-related liabilities4     
Interest and dividends payable   000
Debt   331
Restructuring reserve0     
Other undisclosed current liabilities1 9611
Total current liabilities:10 141696
Noncurrent Liabilities
Long-term debt and lease obligation1  369
Long-term debt, excluding current maturities   369
Operating lease, liability1 
Liabilities, other than long-term debt  2 00
Deferred rent credit  2
Other liabilities    00
Other undisclosed noncurrent liabilities(1)     
Total noncurrent liabilities:1 2369
Total liabilities:11 16191515
Stockholders' equity
Stockholders' equity attributable to parent143 17085428
Common stock0 0000
Additional paid in capital820 694536427424
Accumulated other comprehensive income (loss)0 (0)(0)(0)(0)
Accumulated deficit(677) (523)(451)(423)(396)
Total stockholders' equity:143 17085428
TOTAL LIABILITIES AND EQUITY:154 1871041943

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:   10  
Operating expenses(53) (73)(31)(26)(26)
Operating loss:(53) (73)(21)(26)(26)
Nonoperating income (expense)2 (0)(5)011
Investment income, nonoperating2 4100
Other nonoperating income (expense)  (3)(6)011
Interest and debt expense  (0)(1)(1)(1)
Loss before gain (loss) on sale of properties:(51) (73)(28)(27)(16)
Other undisclosed net income  0   
Net loss available to common stockholders, basic:(51) (73)(28)(27)(16)
Dilutive securities, effect on basic earnings per share  (0)  (0)
Net loss available to common stockholders, diluted:(51) (73)(28)(27)(16)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(51) (73)(28)(27)(16)
Other comprehensive income (loss)(0) (0)(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(51) (73)(28)(27)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: